ADS-ADEA 2016* , ,
Presentations this author is a contributor to:
Earlier onset of exposure and greater early pharmacokinetic and pharmacodynamic effects for faster-acting insulin aspart vs. insulin aspart using continuous subcutaneous insulin infusion (#162)
9:45 AM
Tim Heise
ADS Clinical Orals - Type 1 Diabetes
Faster-acting insulin aspart demonstrates higher early insulin exposure and greater early glucose-lowering effect vs. insulin aspart across a clinically relevant dose range (#165)
10:30 AM
Tim Heise
ADS Clinical Orals - Type 1 Diabetes